| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10911035 | Lung Cancer | 2013 | 5 Pages |
Abstract
We could not demonstrate the add-on effect of intermittent erlotinib on pemetrexed in a second-line setting for patients with non-squamous NSCLC without EGFR mutations.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Seigo Minami, Takashi Kijima, Masanari Hamaguchi, Takeshi Nakatani, Taro Koba, Ryo Takahashi, Yoshiko Takeuchi, Hiroshi Kida, Izumi Nagatomo, Suguru Yamamoto, Isao Tachibana, Kiyoshi Komuta, Ichiro Kawase,